FDA Approves the First Oral PCSK9 Inhibitor, Ending the Injection-Only Era for a Major Cholesterol Drug Class

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for adults with high LDL cholesterol. What it changes and what remains unknown.

Have A Referral?